Cargando…

Pharmacists’ experiences on adverse drug reaction: 10 years later

Adverse drug reaction (ADR) is one of the leading public health concerns associated with high mortality rate. Healthcare professionals, particularly pharmacists, have a significant role in monitoring and preventing ADRs. This study was conducted on Malaysian Pharmaceutical Society (MPS) pharmacists...

Descripción completa

Detalles Bibliográficos
Autores principales: Karuppannan, Mahmathi, Mohamad Rizal, Nur Azzrin Nisha, Wong, Kok-Thong, Mohd. Ali, Salmiah, Ting, Kang-Nee, Boardman, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559835/
https://www.ncbi.nlm.nih.gov/pubmed/36249772
http://dx.doi.org/10.3389/fphar.2022.932942
_version_ 1784807710906122240
author Karuppannan, Mahmathi
Mohamad Rizal, Nur Azzrin Nisha
Wong, Kok-Thong
Mohd. Ali, Salmiah
Ting, Kang-Nee
Boardman, Helen
author_facet Karuppannan, Mahmathi
Mohamad Rizal, Nur Azzrin Nisha
Wong, Kok-Thong
Mohd. Ali, Salmiah
Ting, Kang-Nee
Boardman, Helen
author_sort Karuppannan, Mahmathi
collection PubMed
description Adverse drug reaction (ADR) is one of the leading public health concerns associated with high mortality rate. Healthcare professionals, particularly pharmacists, have a significant role in monitoring and preventing ADRs. This study was conducted on Malaysian Pharmaceutical Society (MPS) pharmacists who worked at the hospitals, health clinics, and community pharmacies to determine if pharmacists’ experiences on ADRs are still the same 10 years later. In 2010, a postal survey and in 2020, an online survey were conducted among these pharmacists. A total of 472 pharmacists and 208 participated in 2010 and 2020, respectively. About 82% and 90% of hospital/health clinic pharmacists (HCPs) observed an ADR over the last 6 months in 2010 and 2020, while 60% and 100% community pharmacists in 2010 and 2020 observed an ADR, respectively. Perindopril was the top drug (HCPs: p = 0.657; CPs: p = 0.98), and rash was the top ADR reported by the pharmacists in both years (HCPs: p < 0.001; CPs: p = 0.679). The most common actions taken by HCPs in 2010 were to report the ADR (p = 0.343), while in 2020, most HCPs explained to patients regarding the reaction (p = 0.061), which was also the same in the CP group in 2020 (p = 0.958). The top factor encouraging ADR reporting in both years and both pharmacist groups was the high degree of severity of the reaction (HCPs: p < 0.001; CPs: p = 0.769). While the top factors discouraging ADR reporting were a lack of information from the affected patients (HCPs: p = 0.2; CPs: p = 0.656), reaction is widely known (HCPs: p = 0.001; CPs: p = 0.144) and uncertainty of the causal relationship (HCPs: p = 0.169; CPs: p = 0.609). Majority of the pharmacists agreed that severe reactions should be reported (HCPs: p = 0.158; CPs: p = 0.501) and the main aim for reporting is to measure the incidence of ADRs (HCPs: p = 0.148; CPs: p = 0.762). Despite being able to identify ADRs during the daily practice, many pharmacists especially community pharmacists are not reporting them. There is a misconception on the purpose of reporting ADRs. An interventional program and ADR reporting training would be a useful step in improving ADR reporting practice.
format Online
Article
Text
id pubmed-9559835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95598352022-10-14 Pharmacists’ experiences on adverse drug reaction: 10 years later Karuppannan, Mahmathi Mohamad Rizal, Nur Azzrin Nisha Wong, Kok-Thong Mohd. Ali, Salmiah Ting, Kang-Nee Boardman, Helen Front Pharmacol Pharmacology Adverse drug reaction (ADR) is one of the leading public health concerns associated with high mortality rate. Healthcare professionals, particularly pharmacists, have a significant role in monitoring and preventing ADRs. This study was conducted on Malaysian Pharmaceutical Society (MPS) pharmacists who worked at the hospitals, health clinics, and community pharmacies to determine if pharmacists’ experiences on ADRs are still the same 10 years later. In 2010, a postal survey and in 2020, an online survey were conducted among these pharmacists. A total of 472 pharmacists and 208 participated in 2010 and 2020, respectively. About 82% and 90% of hospital/health clinic pharmacists (HCPs) observed an ADR over the last 6 months in 2010 and 2020, while 60% and 100% community pharmacists in 2010 and 2020 observed an ADR, respectively. Perindopril was the top drug (HCPs: p = 0.657; CPs: p = 0.98), and rash was the top ADR reported by the pharmacists in both years (HCPs: p < 0.001; CPs: p = 0.679). The most common actions taken by HCPs in 2010 were to report the ADR (p = 0.343), while in 2020, most HCPs explained to patients regarding the reaction (p = 0.061), which was also the same in the CP group in 2020 (p = 0.958). The top factor encouraging ADR reporting in both years and both pharmacist groups was the high degree of severity of the reaction (HCPs: p < 0.001; CPs: p = 0.769). While the top factors discouraging ADR reporting were a lack of information from the affected patients (HCPs: p = 0.2; CPs: p = 0.656), reaction is widely known (HCPs: p = 0.001; CPs: p = 0.144) and uncertainty of the causal relationship (HCPs: p = 0.169; CPs: p = 0.609). Majority of the pharmacists agreed that severe reactions should be reported (HCPs: p = 0.158; CPs: p = 0.501) and the main aim for reporting is to measure the incidence of ADRs (HCPs: p = 0.148; CPs: p = 0.762). Despite being able to identify ADRs during the daily practice, many pharmacists especially community pharmacists are not reporting them. There is a misconception on the purpose of reporting ADRs. An interventional program and ADR reporting training would be a useful step in improving ADR reporting practice. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9559835/ /pubmed/36249772 http://dx.doi.org/10.3389/fphar.2022.932942 Text en Copyright © 2022 Karuppannan, Mohamad Rizal, Wong, Mohd. Ali, Ting and Boardman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Karuppannan, Mahmathi
Mohamad Rizal, Nur Azzrin Nisha
Wong, Kok-Thong
Mohd. Ali, Salmiah
Ting, Kang-Nee
Boardman, Helen
Pharmacists’ experiences on adverse drug reaction: 10 years later
title Pharmacists’ experiences on adverse drug reaction: 10 years later
title_full Pharmacists’ experiences on adverse drug reaction: 10 years later
title_fullStr Pharmacists’ experiences on adverse drug reaction: 10 years later
title_full_unstemmed Pharmacists’ experiences on adverse drug reaction: 10 years later
title_short Pharmacists’ experiences on adverse drug reaction: 10 years later
title_sort pharmacists’ experiences on adverse drug reaction: 10 years later
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559835/
https://www.ncbi.nlm.nih.gov/pubmed/36249772
http://dx.doi.org/10.3389/fphar.2022.932942
work_keys_str_mv AT karuppannanmahmathi pharmacistsexperiencesonadversedrugreaction10yearslater
AT mohamadrizalnurazzrinnisha pharmacistsexperiencesonadversedrugreaction10yearslater
AT wongkokthong pharmacistsexperiencesonadversedrugreaction10yearslater
AT mohdalisalmiah pharmacistsexperiencesonadversedrugreaction10yearslater
AT tingkangnee pharmacistsexperiencesonadversedrugreaction10yearslater
AT boardmanhelen pharmacistsexperiencesonadversedrugreaction10yearslater